Officials with Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, have announced the compnay has been awarded a new National Institute of Allergy and Infectious Diseases (NIAID) contract for $1.4 M for the base period, with options to exercise an additional $2.52 M over two to three years to develop its broad-spectrum antiviral therapeutics to address a variety of viral diseases.
The company's class of molecules has been shown in pre-clinical tests to inhibit diverse viral pathogens including Ebola, influenza A & B, dengue, West Nile, Lassa fever, respiratory syncytial virus and human coronaviruses.
“Kineta’s small molecule compounds trigger a natural immune response by targeting processes that activate the innate human immune transcription factor, IRF-3, a critical responder that drives antiviral gene expression to suppress viral replication,” Kristin Bedard, Director and Head of Kineta’s Virology Program said in a press release. “Direct acting antivirals typically have selective action against only a single virus with a high risk of eliciting drug resistance. Host-directed antiviral drugs will be broad spectrum with limited susceptibility to drug resistance.”
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201500011C.
The growing market for immunotherapy treatments isn’t just focused on cancer. Seattle biotech Kineta just landed a federal contract from the National Institutes of Health for about $4 million to develop an immunotherapy treatment which would treat a variety of infectious diseases, such as the flu, dengue fever, Ebola and others.